TScan Therapeutics, Inc.
TCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.17 | 0.10 | -0.13 |
| FCF Yield | -14.34% | -18.36% | -21.86% | -7.71% |
| EV / EBITDA | -4.74 | -3.25 | -3.72 | -8.33 |
| Quality | ||||
| ROIC | -15.44% | -14.13% | -11.77% | -10.81% |
| Gross Margin | 69.45% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.91 | 0.90 | 1.10 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -20.77% | -24.86% | -36.56% | -40.75% |
| Free Cash Flow Growth | 1.90% | 11.69% | -38.23% | 3.37% |
| Safety | ||||
| Net Debt / EBITDA | 2.16 | 2.04 | 1.74 | 2.37 |
| Interest Coverage | -53.01 | -56.10 | -53.39 | -46.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -745.46 | 0.00 | 0.00 | 0.00 |